Advances in Imaging for Kidney Cancer Diagnosis and Management

Kidney cancer specialists discuss recent advances in imaging for diagnosis and disease management, highlighting sestamibi and zirconium scans.

EP: 1.A Growing Incidence of Renal Masses

EP: 2.Diagnostic Tests for Kidney Cancer

EP: 3.Limitations of Conventional Imaging for Assessing Renal Masses

EP: 4.The Role of a Multidisciplinary Team in Managing Kidney Cancer

EP: 5.Staging and Treatment Decisions for Kidney Cancer

Now Viewing

EP: 6.Advances in Imaging for Kidney Cancer Diagnosis and Management

EP: 7.Overview of Clinical Trials for New Imaging Options for Kidney Cancer

EP: 8.Potential Impact of PET/CT Imaging on Improving Patient Care

Related Videos

Related Content

Advertisement

June 6th 2025

Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

Hannah Clarke

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

June 5th 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

June 5th 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

May 19th 2025

Patient selection for cytoreductive nephrectomy in 2025

Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.

Related Content

Advertisement

June 6th 2025

Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal

Hannah Clarke

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

June 5th 2025

Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma

Hannah Clarke

The new drug application is backed by data from the phase 2/3 FRUSICA-2 trial.

June 5th 2025

Zanzalintinib plus nivolumab shows safety, efficacy for stage 4 RCC

Benjamin P. Saylor

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke

The approvals are supported by findings from the phase 3 CheckMate-67T trial.

May 19th 2025

Patient selection for cytoreductive nephrectomy in 2025

Daniel D. Shapiro, MD, FACS E. Jason Abel, MD, FACS

"Appropriate patient selection for CN is a highly individualized process that is improved with a multidisciplinary approach," write the authors.